Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially reduced the lipoprotein(a) levels in patients w...

Full description

Bibliographic Details

Published in:	Journal of Cardiovascular Development and Disease
Main Authors:	Tomoaki Okada, Toru Miyoshi, Masayuki Doi, Kazumasa Nosaka, Ryu Tsushima, Satoko Ugawa, Wataru Takagi, Masahiro Sogo, Masahiko Takahashi, Hiroshi Ito
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Subjects:	evolocumab pitavastatin lipoprotein(a) percutaneous coronary intervention hypolipidemic agents myocardial infarction
Online Access:	https://www.mdpi.com/2308-3425/9/5/153